Citations - Bosse Tjalling

CONCLUSIONS: Stratification of VSCC by p16- and p53-IHC has potential to be used routinely in diagnostic pathology. It results in the identification of three clinically distinct subtypes and may be used to guide treatment and follow-up, and in stratifying patients in future clinical trials.... Read more
Published on: 2020-09-25
Source: Bosse Tjalling
By: Kim E Kortekaas
CONCLUSIONS: Stratification of VSCC by p16- and p53-IHC has potential to be used routinely in diagnostic pathology. It results in the identification of three clinically distinct subtypes and may be used to guide treatment and follow-up, and in stratifying patients in future clinical trials.... Read more
Published on: 2020-09-25
Source: Bosse Tjalling
By: Kim E Kortekaas
CONCLUSIONS: Stratification of VSCC by p16- and p53-IHC has potential to be used routinely in diagnostic pathology. It results in the identification of three clinically distinct subtypes and may be used to guide treatment and follow-up, and in stratifying patients in future clinical trials.... Read more
Published on: 2020-09-25
Source: Bosse Tjalling
By: Kim E Kortekaas
CONCLUSIONS: Stratification of VSCC by p16- and p53-IHC has potential to be used routinely in diagnostic pathology. It results in the identification of three clinically distinct subtypes and may be used to guide treatment and follow-up, and in stratifying patients in future clinical trials.... Read more
Published on: 2020-09-25
Source: Bosse Tjalling
By: Kim E Kortekaas
CONCLUSION: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLEmut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as... Read more
Published on: 2020-08-05
Source: Bosse Tjalling
By: Alicia León-Castillo
CONCLUSION: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLEmut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as... Read more
Published on: 2020-08-05
Source: Bosse Tjalling
By: Alicia León-Castillo
CONCLUSION: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type. Patients with POLEmut EC had an excellent RFS in both trial arms. EC molecular classification should be incorporated in the risk stratification of these patients as... Read more
Published on: 2020-08-05
Source: Bosse Tjalling
By: Alicia León-Castillo
CONCLUSIONS: EC-inspired molecular classification provides independent prognostic information in ENOC. Our findings support investigating molecular subtype-specific management recommendations for patients with ENOC; for example, subtypes may provide guidance when fertility-sparing treatment is desired. Similarities between ENOC and EC suggest that patients with ENOC may benefit from management strategies applied to... Read more
Published on: 2020-08-02
Source: Bosse Tjalling
By: Pauline Krämer

Other Resources

Other Citations

Other Citations

News by Specialization

News by Specialization

Videos

Selection of Videos by Specialization

Latest News

Latest News

Translate »